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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N ations around the world are working tofind the best ways to manage theongoing coronavirus disease 2019
(COVID-19) pandemic. They are pairing ef-
forts to detect viral infection, prevent trans-
mission, and manage patients who are infected,
with knowledge of previous seasonal corona-
virus outbreaks and growing experience with
COVID-19 to craft best-evidence guidance.
Recent data show that as many as 25% of pa-
tients who are infected remain asymptomatic,
and viral shedding may begin up to 48 hours
before symptoms appear. Worldwide regulatory
authorities remain committed to guidance that
is clearly evidence-based. As new information
appears, updated guidance produces many sim-
ilarities, and some differences in these guidance
documents, in part deriving from regional and
population differences. We here review guid-
ance for detecting and mitigating COVID-19
infections in patients who are on dialysis,
noting where there is universal agreement and
where there are differences.
Preventing epidemic spread of infection re-
quires early recognition of infection, isolation,
and meticulous tracking of contacts. Reverse
transcriptase polymerase chain reaction test
kits developed early in this pandemic in Berlin,
and deployed by the World Health Organiza-
tion, assisted many Asian and European
countries in limiting infection and “lowering
the peak” of infected individuals over time.
Limited availability and slow deployment of
such test kits in places like parts of the United
States and Italy hindered efforts to prevent
epidemic spread, with rapidly rising numbers
of patients overwhelming parts of the health
care system. Once the pandemic was estab-
lished, efforts switched from prevention to
mitigation—with efforts to reduce person-to-
person viral transmission and protect the
most vulnerable parts of the population. Key
features of mitigation include patient and
health care worker (HCW) education and
implementation of strategies to prevent further
spread such as social distancing, widespread use
of face masks for patients with suspected orconfirmed disease to limit transmission, and
appropriate personal protective equipment
(PPE) for HCWs and others who have direct
contact with patients infected with COVID-19.
Patients on in-center hemodialysis are
particularly vulnerable to COVID-19 for 2
reasons. First, while the world’s population
shelters at home to avoid contact with infected
individuals, patients who are on in-center
dialysis must come together for hours thrice
weekly and travel to and from these treatments,
increasing possible exposure. Second, patients
with end-stage kidney disease who acquire the
infection are at higher risk of complication and
death due to older age and common comor-
bidities that increase mortality risk, including
diabetes, heart disease, obesity, and hyperten-
sion; and in part because patients with end-
stage kidney disease may have impaired im-
mune systems. To provide information on how
to best protect these patients from COVID-19,
we examined the guidance provided by the US
Centers for Disease Control and Prevention
(CDC), the European Renal Association–
European Dialysis and Transplant Association,
Italy, and India,1–5 noting where they provide
similar guidance and where there are differ-
ences (Tables 1 and 2):
(i) Education of patients and HCWs: All
guidance documents emphasize the basics
of hand and respiratory hygiene, coughing
etiquette, and use of PPE.
(ii) Screening and recognition of symptoms:
All guidance documents advise screening
patients for most common symptoms
including fever, new cough, or dyspnea.
There is less uniform screening for sore
throat, myalgia, chills, fatigue, conjuncti-
vitis, diarrhea, and rhinorrhea. There is
also consistency in screening for travel to
endemic areas, asking patients to call
ahead if they have symptoms of infection
or potential exposure, and establishing a
triage protocol prior to patient arrival at
the facility. All advise masking patients
prior to entering the facility and
throughout the treatment, designating a1
Table 1 | A comprehensive list of approaches to prevention and control of COVID-19 infection in
dialysis facilities
Education
Education of patients and related individuals
1. Hand and respiratory hygiene and coughing etiquette
2. Use of masks
3. Basic signs and symptoms associated with the disease
4. Place signs to direct patients who are symptomatic or have been exposed to a designated screening location in an
appropriate space
Education of HCWs
1. Training for appropriate use of PPE
2. Reemphasis of universal precautions for infection control in the facility
Screening
1. Instruct all patients to call ahead
2. Temperature check for all patients on arrival and departure
3. Implement triage protocol for patients who are suspected to have COVID-19
4. Transfer sicker patients to emergency departments
5. Perform screening RT-PCR test in all patients who are on dialysis
6. Prioritize testing of dialysis personnel
Management of patients with symptoms or illness
Administrative preparedness
1. Create backup lists if staff become sick
2. Create COVID-19 teams
3. Implement workflow to protect nonworking HCWs from potential exposure to healthy backup
4. Cross-train staff when applicable
Transportation
1. Personal transportation: use, fixed route, no public, driver mask
2. EMT/ambulance: CDC guidance
Facility workflow
1. Define separate area and shift for patients with symptoms (COVID-19–positive section)
2. Separate all patients who are COVID-19–positive 6 feet in all directions from each other
3. PPE utilization
a. Provide all patients a surgical mask
b. Use eye and face protection for management of patients who are suspected or positive for disease
4. Use separate medical equipment for patients with suspected or positive disease
5. Maintain routine cleaning and disinfection procedures
Other recommendations
Clearance of recovered patients
1. Negative RT-PCR test
2. Resolution of symptoms
Return-to-work for recovered HCWs
1. Best-evidence guidance using timing after symptom cessation, negative PCR testing, and serologic testing
Routine care for patients on dialysis
1. Minimize face-to-face physician rounding
2. Distance HCWs during team rounds
3. Consider telehealth for care planning
4. Prioritize access to surgeries and procedures
5. Consider decreased frequency during peak periods
CDC, US Centers for Disease Control and Prevention; COVID-19, coronavirus disease 2019; EMT, emergency medical transport; HCW,
health care worker; PCR, polymerase chain reaction; PPE, personal protective equipment; RT-PCR, reverse transcriptase polymerase
chain reaction.
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2separate waiting area for screening or
waiting in a personal vehicle for screening,
and treating patients under investigation
(PUIs), those with moderate or high
likelihood of disease, before testing
confirmation, as potentially positive.
(iii) PPE: All guidance documents advise use
of surgical masks for patients and HCWs.
While in the United States, N95 or higher-
level respirators are advised if available,
elsewhere N95 masks are advised only for
aerosol-generating procedures. Surgical
masks are otherwise advised for all HCWsincluding those cleaning machines. All
advise disposable gloves, and most advise
face shields or goggles. Some suggest hair
covers and shoe covers. In the United
States, the CDC advises PPE competency
evaluation for staff and auditing compli-
ance with PPE and hand hygiene, advice
not documented in other guidance
documents.
(iv) Managing patients who are symptomatic
or positive for COVID-19: This is one area
where there are differences in guidance
around the world, although mostKidney International (2020) -, -–-
Table 2 | Comparison of COVID-19 guidance provided for different geographic regions in the world
USAa Europe Asia/other
Education
Patients
Basic hygiene and disease education X X X
HCWs
PPE training and evaluation X N/A N/A
Screening
Symptom check on arrival X X X
Temperature check on arrival and departure X X X
Screening diagnostic test in all patients on dialysis NSG NSG NSG
Management
Administrative
COVID-19 teams X X X
Backup lists X N/A N/A
Facility workflow
Dedicated space and shift X X X
Surgical face mask to all patients X X X
Routine cleaning and disinfection procedures X X X
Supply chain
Recycling of PPE X X N/A
Other recommendations
Transportation Xb NSG NSG
Return-to-work for HCWs Xb NSG NSG
Clinical management of PUIs or patients who are infected RS RS RS
COVID-19, coronavirus disease 2019; HCW, health care worker; N/A, not available; NSG, no specific guidance; PPE, personal protective
equipment; PUI, patient under investigation; RS, region-specific with different recommendations; X, availability of a recommendation
that is similar across different regions.
aUS guidelines are based on Centers for Disease Control and Prevention’s recommendations and published recommendations to date.
bLimited guidance from the Centers for Disease Control and Prevention.
Data are excerpted from available publications and are not intended to be inclusive of all available local documents.
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Kidney International (2020) -, -–-guidance is similar. All guidance docu-
ments advise cohorting multiple
confirmed cases or PUIs and assigning
designated staff to care for them. The
majority suggest that supplies be posi-
tioned close to hemodialysis chairs and
nursing stations to ensure adherence to
hand and respiratory hygiene. Routine
cleaning and disinfection procedures are
recommended by all guidance documents.
For stable PUIs or patients with confirmed
coronavirus, some countries advise hos-
pitalization and admission to an airborne
infection isolation room. The US CDC
specifically states that an airborne infec-
tion isolation room is not needed in the
outpatient management of COVID-19
dialysis. While Asian guidance docu-
ments advise that PUIs be admitted to an
infectious disease ward, others advise that
PUIs and patients who are confirmed
positive can be dialyzed in the outpatient
unit, if clinically stable. This is to be per-
formed in a designated COVID-19 facility,
dialysis shift, an isolation room within a
facility that treats noninfected patients, or
in a separate room with the door closed. If
none of these are available, then the advice
is to dialyze these patients at the end of theline or corner position of the facility, with
separation from other patients by 6 feet in
all directions. For patients who are ill with
progressive dyspnea, organ dysfunction,
or acute respiratory distress syndrome, all
guidance documents advise
hospitalization.
(v) Resource utilization: The US CDC discusses
supply chain management, preserving and
prioritizing PPE, extended use of eye and
face protection, recycling of PPE, and
alternate PPE. They also discuss sick leave
policy, cross-training and back-up plans,
staff return-to-work guidelines, and after
return-to-work guidance. These recom-
mendations are not provided in publica-
tions from other countries although they
may exist locally. Telemedicine is widely
used worldwide, when technically possible,
to minimize face-to-face contact.
(vi) Home dialysis: There is consistency that
patients on home hemodialysis and peri-
toneal dialysis continue care at home, and
HCWs use telemedicine or other elec-
tronic systems for clinical management,
with home visits if necessary. Imple-
mentation of these recommendations are
likely to be resource- and geography-
dependent.3
ed i to r i a l
4(vii) Some guidance documents advise clini-
cians to consider reducing the frequency
of hemodialysis sessions from 3 to 2 times
weekly in patients who tolerate this
regimen. This would reduce the need to
travel by car or ambulance in the event of
a shortage of these means of transport,
decrease the risk of infection exposure
during transport, and reduce the likeli-
hood of patients on dialysis spreading
infection in the dialysis unit or the hos-
pital. There is consensus to implement
reduced individual dialysis in extreme
shortage crisis conditions.
Why might regional differences in guidance
exist? In countries where early recognition of
endemic infection spread was initiated,
aggressive steps to identify and isolate patients
with COVID-19 and identify their contacts
permitted a prevention plan that limited their
local epidemic. In China, recognition of infec-
tion was initially slow in Wuhan, but aggressive
preventive measures in other parts of the
country were probably successful. While some
European countries have been successful in
containment and prevention, others were less
successful and focused on mitigation strategies.
Availability and use of diagnostic tests have
been major determinants of prevention, best
practice, and mitigation. In the United States,
the limited and slow dispersal of testing ca-
pacity has hindered mitigation efforts. Avail-
ability and utility of serologic tests may allow
accurate identification of patients who have had
COVID-19 and developed immunity, including
those who are asymptomatic as well as HCWs
who are no longer at risk, hence allowing them
to return to work.
Despite its major unwanted adverse conse-
quences, this major health crisis has perhaps
taught us major lessons. Some of these learned
so far include:
(i) Many people have previously warned that
worldwide preparedness for previously
unknown epidemic illness is inevitable,
and that we must prepare now for this
likelihood. This warning has previously
received little attention outside Asia. We
now know the importance and priority of
such readiness.
(ii) Early recognition of new infectious dis-
eases requires a new discipline, awareness,
and vigilance. This will require a world-
wide effort to record and report symptom
clusters, changes in hospitalization,
morbidity and mortality rates, and a 21st-century epidemiologic registry. Analytic
tools can be used to develop new algo-
rithms to assess changes in population
health. A new discipline of worldwide
surveillance and early recognition will
allow countries to contain infection and
prevent pandemics.
(iii) If we have a reactive approach, responding
to spreading infection rather than antici-
pating and containing it, we will fail. A well-
designed proactive approach that includes
early case identification, careful contact
mapping and isolation, and swift imple-
mentation of protocols will permit infection
containment and substantially reduce pop-
ulation exposure, morbidity, and mortality.
(iv) If implemented appropriately, infection
prevention works. This can be observed in
countries such as Taiwan, New Zealand,
and Singapore. Information to date also
suggests a limited in-facility transmission
in patients on dialysis, most likely related
to an infection prevention culture that has
been imbedded in the care of these
vulnerable patients.
(v) Once a pandemic is established, aggressive
mitigation techniques such as social
distancing, testing for specific organisms,
and serologic evidence of infection and
immunity are critically important.
(vi) Equipment and personnel shortages are
predictable during a pandemic. National
and perhaps worldwide preparedness for
this will require new flexible algorithms
and coordinating and sharing resources.
The 20th-century model of independent,
sometimes competing health care systems
using just-in-time ordering to minimize
inefficient shelving of supplies, will need
21st-century updating to allow interna-
tional stockpiling of critical equipment
with flexible plans to anticipate needs and
quickly move them as needed.
(vii) To prepare for the next pandemic, a
multinational research group should be
assembled to investigate all aspects of the
organism and the host response, including
the source reservoir, genetics, host response,
vaccination and more. Regional puzzles
need investigation: for example, why in New
York is there a predominance of African
Americans affected by COVID-19 and
complications leading to death? Frame-
works for international trials of vaccines and
medications should be prepared and ready
to dispatch.Kidney International (2020) -, -–-
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Kidney International (2020) -, -–-As the COVID-19 pandemic spread around
the world, lessons learned from its challenges
have shaped the guidance offered in each re-
gion. It is striking that this guidance, as it
matured around the globe, has largely come
together in uniformity. If we are to learn from
this experience and be better prepared for the
next epidemic challenge, it will be wise to think
globally, act locally, and create an international
structure to anticipate and guide best practice.DISCLOSURE
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